Iodol

Summary

Iodol (CHEMBL2105006) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 570.68 Da · C4HI4N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105006
Name	Iodol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	66602
Molecular formula	C4HI4N
Molecular weight	570.68
InChIKey	VJOVAKSZILJDBB-UHFFFAOYSA-N

SMILES: C1(=C(NC(=C1I)I)I)I

IUPAC name: 2,3,4,5-tetraiodo-1H-pyrrole

Also known as: Iodol, Iodopyrrole, NSC-36714, IODOL

Patent coverage: 117 distinct patent families (224 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).